Foundations Investment Advisors LLC acquired a new position in PetIQ, Inc. (NASDAQ:PETQ – Get Rating) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 18,300 shares of the company’s stock, valued at approximately $326,000. Foundations Investment Advisors LLC owned approximately 0.06% of PetIQ at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in PETQ. BNP Paribas Arbitrage SA lifted its holdings in PetIQ by 20.2% in the 4th quarter. BNP Paribas Arbitrage SA now owns 5,825 shares of the company’s stock worth $132,000 after buying an additional 978 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of PetIQ by 55.5% in the 4th quarter. Principal Financial Group Inc. now owns 76,248 shares of the company’s stock worth $1,732,000 after purchasing an additional 27,226 shares during the last quarter. Allianz Asset Management GmbH increased its position in shares of PetIQ by 87.9% in the 4th quarter. Allianz Asset Management GmbH now owns 536,768 shares of the company’s stock worth $12,190,000 after purchasing an additional 251,121 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of PetIQ by 39.9% in the 4th quarter. Eagle Asset Management Inc. now owns 276,156 shares of the company’s stock worth $6,299,000 after purchasing an additional 78,806 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of PetIQ in the 4th quarter worth about $14,887,000.
PetIQ Trading Down 0.1 %
Shares of NASDAQ:PETQ opened at $9.74 on Monday. The company has a quick ratio of 1.54, a current ratio of 2.88 and a debt-to-equity ratio of 1.69. PetIQ, Inc. has a fifty-two week low of $8.60 and a fifty-two week high of $27.09. The firm has a 50-day simple moving average of $14.01 and a 200 day simple moving average of $17.50.
Analyst Ratings Changes
Separately, Raymond James dropped their target price on shares of PetIQ from $29.00 to $21.00 in a research report on Wednesday, August 10th.
PetIQ Company Profile
PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications.
- Get a free copy of the StockNews.com research report on PetIQ (PETQ)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.